We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
General Electric Company’s (GE - Free Report) Global Research Center recently inked a $2.9-million three-year partnership deal with the Defense Advanced Research Projects Agency (‘DARPA’). The company has also strengthened its long standing relationship with Canadian National Railway Company (CNI - Free Report) , by extending its class I’s 200-unit order (placed in December 2017) secured from the latter.
Inside the Headlines
Under the $2.9-million pact, the GE Bioelectronic medicine team is trying to invent non-invasive medical devices for treating diabetes. Creation of such state-of-the-art alternative treatment devices can replace the traditional monitoring and drug treatment approaches of diabetes which are time consuming and often produce side-effects for patients.
The GE Bioelectronic medicine team has possibly developed techniques to create such non-invasive devices. These gadgets will be able to restore nerve signals to a superior state that easily stimulates metabolic biosystems with lesser side effects and greater accuracy.
In fact, the company’s research team will be demonstrating a non-invasive stimulation technique in this week’s DARPA’s Washington D60 symposium. The technique will likely treat or reverse diabetes in pre-clinical models, as against the conventionally used drugs, of late. The team anticipates that the technique will aid in preventing the onset of metabolic dysfunction (linked with diabetes), thereby carving clinical usage opportunities.
In addition to this, the Canadian National Railway will be acquiring 60 additional Tier 4 Evolution Series locomotives from General Electric. These locomotives comprise the company’s premium Trip Optimizer System, Distributed Power LOCOTROL eXpanded Architecture and its non-imitable E Transportation’s GoLINC Platform. The locomotives optimize train handling, fuel utilization and brake control, and also enhance its power distribution system.
General Electric is poised to grow on the back of stronger innovation, strategic restructuring moves, increased international presence and robust end-market sales. However, over the past three months, shares of this Zacks Rank #3 (Hold) companies have lost 8.8%, as against 0.7% growth registered by the industry.
Stocks to Consider
A few better-ranked stocks in the same space are listed below:
Carlisle Companies Incorporated (CSL - Free Report) holds a Zacks Rank #2. The company delivered an average positive earnings surprise of 12.85%, over the trailing four quarters.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
GE Partners With DARPA & Extends CN Rail Contract
General Electric Company’s (GE - Free Report) Global Research Center recently inked a $2.9-million three-year partnership deal with the Defense Advanced Research Projects Agency (‘DARPA’). The company has also strengthened its long standing relationship with Canadian National Railway Company (CNI - Free Report) , by extending its class I’s 200-unit order (placed in December 2017) secured from the latter.
Inside the Headlines
Under the $2.9-million pact, the GE Bioelectronic medicine team is trying to invent non-invasive medical devices for treating diabetes. Creation of such state-of-the-art alternative treatment devices can replace the traditional monitoring and drug treatment approaches of diabetes which are time consuming and often produce side-effects for patients.
The GE Bioelectronic medicine team has possibly developed techniques to create such non-invasive devices. These gadgets will be able to restore nerve signals to a superior state that easily stimulates metabolic biosystems with lesser side effects and greater accuracy.
In fact, the company’s research team will be demonstrating a non-invasive stimulation technique in this week’s DARPA’s Washington D60 symposium. The technique will likely treat or reverse diabetes in pre-clinical models, as against the conventionally used drugs, of late. The team anticipates that the technique will aid in preventing the onset of metabolic dysfunction (linked with diabetes), thereby carving clinical usage opportunities.
In addition to this, the Canadian National Railway will be acquiring 60 additional Tier 4 Evolution Series locomotives from General Electric. These locomotives comprise the company’s premium Trip Optimizer System, Distributed Power LOCOTROL eXpanded Architecture and its non-imitable E Transportation’s GoLINC Platform. The locomotives optimize train handling, fuel utilization and brake control, and also enhance its power distribution system.
General Electric is poised to grow on the back of stronger innovation, strategic restructuring moves, increased international presence and robust end-market sales. However, over the past three months, shares of this Zacks Rank #3 (Hold) companies have lost 8.8%, as against 0.7% growth registered by the industry.
Stocks to Consider
A few better-ranked stocks in the same space are listed below:
Federal Signal Corporation (FSS - Free Report) sports a Zacks Rank of 1 (Strong Buy). The company pulled off an average positive earnings surprise of 22.48% over the past four quarters. You can see the complete list of today’s Zacks #1 Rank stocks here.
Carlisle Companies Incorporated (CSL - Free Report) holds a Zacks Rank #2. The company delivered an average positive earnings surprise of 12.85%, over the trailing four quarters.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>